TAAR1 and gastric cancer: When human gastric cancer cell line BGC-823 was treated with Tα1 or Tα1-iRGD at doses that ranged from 0.03125 μmol/mL to 0.5000 μmol/mL (Figure 5B), Tα1 exhibited no antiproliferative activity even at high concentrations (beyond 0.25 μmol/mL), By contrast, Tα1-iRGD exhibited a significant proliferative activity at high concentrations (from 0.125 μmol/mL and above).This finding indicated that the addition of the iRGD motif can improve the antiproliferative activity of Tα1 in the human gastric cancer cell line BGC-823.